Last reviewed · How we verify
Quick response: Amoxicillin for 3 days
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking. Used for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, otitis media, sinusitis), Helicobacter pylori eradication (as part of combination therapy).
At a glance
| Generic name | Quick response: Amoxicillin for 3 days |
|---|---|
| Also known as | Quick response (3 days) |
| Sponsor | University Hospital, Montpellier |
| Drug class | Beta-lactam antibiotic (aminopenicillin) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, preventing the cross-linking of peptidoglycan strands. This disrupts cell wall integrity, leading to bacterial cell lysis and death. It is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, otitis media, sinusitis)
- Helicobacter pylori eradication (as part of combination therapy)
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reaction / anaphylaxis
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: